<div id="readability-page-1"><div id="parent_top_div">Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. &#34;The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development,&#34; Dr Reddy's CEO Erez Israeli said. He further said:&#34;With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients.&#34; The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. &#34;As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,&#34; he noted. In Canada, Dr Reddy's Semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise, the company said. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection, the statement said.</div></div>

如瑞迪博士

藥明康德已在加拿大推出其用於 2 型糖尿病的仿製 Semaglutide 注射劑，成為在獲得加拿大衞生部合規通知後首批推出該產品的公司之一。該注射劑提供 2 毫克和 4 毫克的預填充筆，設計為每週使用一次。首席執行官 Erez Israeli 強調了公司致力於提供高質量 GLP-1 療法並擴大全球市場準入的承諾

如瑞迪博士實驗室在加拿大推出了仿製的 Semaglutide 注射劑